Cardiology

Back to articles

Dulaglutide improves renal and CV outcomes in patients with type 2 diabetes

KEY POINT

Data from the REWIND (Researching Cardiovascular Events with a Weekly Incretin in Diabetes) trial published in Lancet showed that use of once-weekly dulaglutide (Trulicity—Eli Lilly) compared with placebo reduced the risk of adverse cardiovascular (CV) and renal events in patients with type 2 diabetes, including those with and without established CV disease (CVD).